Alternatives to Infera

Recursion runs AI drug discovery as a lab-in-the-loop engine — automated cellular imaging at scale feeding generative chemistry and a clinical pipeline.

SciSpace BioMed Agent runs multi-omics, variant prioritization, and drug repurposing analysis from plain-language biomedical prompts.

Novaflow is an AI data analyst that turns raw biology data into publication-ready figures and methods, no terminal required.

AI enzyme design for pharma manufacturing and life science tools, validated in Pando's own ultra-high-throughput screening lab.

Frekils runs end-to-end real-world evidence studies on your clinical data, with AI writing the statistical code and your patient records never leaving your

AI and computational bionanotechnology R&D partnership that designs field-ready molecular diagnostics for emerging biological threats in days, not 12+ months.

Isomorphic Labs uses AI drug discovery models to design novel molecules and predict how candidate drugs will perform.

Owkin's K Pro is an autonomous AI scientist agent for biopharma R&D, turning multimodal patient data into drug discovery and clinical trial

Recursion OS pairs automated wet labs with AI models for AI drug discovery at up to 2 million weekly experiments.

Evotec is a life-science partner running AI-assisted drug discovery and Just–Evotec Biologics manufacturing.

Silico is Goodfire's interpretability agent for understanding and debugging the internals of your AI models.

Nimbus Therapeutics designs highly selective small-molecule drugs for oncology, immunology, and metabolic disease.

Generative AI drug discovery suite spanning target ID, molecule design, biologics and clinical trial prediction.

Atomwise APEX Protocol screens 10 billion compounds in under 30 seconds for small-molecule drug discovery

Generate Biomedicines uses generative biology to design AI protein therapeutics — antibodies, enzymes, and cytokines — and move them into

Oncology real-world evidence platform combining high-fidelity patient data with AI-assisted cancer research insights.

All-in-human AI foundation models for precision neurology — vBx-1.0 predicts brain activity and therapy response from a blood draw.

Iktos pairs generative AI with robotic lab automation to compress small-molecule drug discovery.

Renamed: Deep 6 AI was acquired by Tempus AI in March 2025 and its trial matching folded into Tempus.

Physics-based molecular simulation with AI for drug discovery and materials design.

Benchling unifies ELN, LIMS, and AI agents for biotech R&D in one cloud platform.

FDA-cleared AI for cancer pathology: prostate, breast, GI and pan-cancer detection on H&E slides, plus Virchow foundation models for research.

Quibim turns MRI, CT and PET scans into regulatory-cleared quantitative imaging biomarkers for prostate, brain, liver, breast and lung.

Google's umbrella health initiative: consumer health info, research tools like AlphaFold, and clinical AI research.

Tempus pairs tumor DNA/RNA sequencing with AI precision oncology analytics to surface treatment and trial matches

Iambic Therapeutics pairs Enchant v3 and NeuralPLexer AI drug discovery with weekly wet lab readouts and a clinical-stage pipeline.

Causal AI drug discovery pairing 20+ petabytes of cellular data with human genetics to find true disease targets

Cradle is an AI protein engineering platform that designs optimised variant plates from your own wet-lab results and feeds each round back into the models.

Cellino's AI-guided optical bioprocessing automates personalized cell therapy manufacturing on the Nebula™ platform.

BenevolentAI applies a decade-built biomedical knowledge graph to drug target discovery and repurposing for biopharma R&D teams.